Renal cell carcinoma (first line metastatic) - pazopanib (TA215)
This guidance has been re-issued after a change to the patient access scheme. Recommendation 1.1 of the guidance has been updated (August 2013).
NICE recommends pazopanib as a possible treatment for some people with renal cell carcinoma (see below).
You should be able to have pazopanib if:
- your renal cell carcinoma is advanced and
- you have not had treatment for advanced renal cell carcinoma before and
- you are mobile and can do light housework or office work.
When assessing people with disabilities, healthcare professionals should bear in mind that a person’s disability might also affect their level of physical activity. They should make adjustments for this.
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their lives. NICE recommended pazopanib because it works as well as other treatments available on the NHS, but costs less.
This page was last updated: 06 November 2013
- Web format
- Full Guidance (PDF)
- TA215 Pazopanib fel triniaeth gyntaf ar gyfer carsinoma celloedd arennol datblygedig: deall canllawiau NICE (fformat MS Word)
Information for the public
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.